Related Experiment Videos
DNA-grading of prostatic carcinoma: prognostic validity and reproducibility
A Böcking1, R Chatelain, U Orthen
1Department of Pathology, Aachen University of Technology, F.R.G.
Anticancer Research
|January 1, 1988
Summary
The DNA-Malignancy-Grade (DNA-MG) offers superior prognostic value for prostate cancer compared to traditional methods. This DNA-based grading system accurately predicts patient survival times in prostatic carcinoma.
Area of Science:
- Oncology
- Pathology
- Biomedical Engineering
Background:
- Prognosticating prostatic carcinoma outcomes is crucial for effective treatment planning.
- Current cytomorphological grading and clinical staging systems have limitations in predicting patient survival.
- Nuclear DNA content variation offers a potential objective marker for malignancy grading.
Purpose of the Study:
- To evaluate the prognostic significance of the DNA-Malignancy-Grade (DNA-MG) in prostatic carcinoma patients.
- To compare the prognostic validity of DNA-MG with cytomorphological grading and clinical staging.
- To assess the reproducibility of the DNA-MG system.
Main Methods:
- 52 prostatic carcinoma patients' transrectal aspiration biopsy smears were analyzed.
- Automated Feulgen restaining and TV-image analysis (Leitz, TAS plus) with an automatic microscope were employed.
- DNA-MG was calculated based on nuclear DNA content variation, ranging from 0.01 to 3.0.
Main Results:
- DNA-MG demonstrated high prognostic validity, outperforming cytomorphological grading.
- Clinical stage had a minor influence on survival time compared to DNA-MG.
- Significant survival differences were observed between DNA-MG groups (0.01-1.5 vs. 1.5-3.0 and 1.0-2.0 vs. 2.0-3.0).
Conclusions:
- The DNA-MG system is a highly valid prognostic tool for prostatic carcinoma.
- DNA-MG provides more reliable prognostic information than cytomorphological grading and clinical staging.
- The DNA-MG system exhibits good intra- and interobserver reproducibility (86.7%).